Crispr/Cas9-mediated DYRK2 deletion in MDA-MB-231 or MDA-MB-468 cells showed that tumors derived from TNBC–DYRK2–deficient cells had significantly slower growth rates and lower tumor burden than those derived from their parental cells. This evidence concerns the gene DYRK2 and neoplasm.